Immune Checkpoint Inhibitors as Independent and Synergistic Drivers of SJS/TEN
A partir de l'analyse de 13 986 839 rapports du système de notification des effets indésirables de la "Food and Drug Administration" (période couverte : 2013-2023) concernant 17 495 patients atteints du syndrome de Stevens-Johnson (SJS) ou d'une nécrolyse épidermique toxique (NET), cette étude examine l'association entre l'utilisation des inhibiteurs de contrôle immunitaire et la survenue de ces manifestations cutanées
Immune checkpoint inhibitors (ICIs) are paradigm-shifting cancer treatments that are increasingly associated with Stevens-Johnson syndrome, toxic epidermal necrolysis (SJS/TEN) and other life-threatening cutaneous reactions. Differentiating ICI-induced true SJS/TEN from SJS/TEN-like reactions is difficult, the latter of which may be distinct lichenoid or bullous reactions. In some cases, ICI-related SJS/TEN-like reactions occur in association with human leukocyte antigen (HLA)–restricted drug culprits like allopurinol, suggesting a 2-hit mechanism. With increasing ICI use, a clearer understanding of their role in SJS/TEN is critical.
JAMA Oncology , article en libre accès, 2025